Advertisement

The Role of Natural Killer T cells in Tumor Immunity

  • Madhav V. Dhodapkar

Keywords

innate immunity cancer vaccine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sogn, J.A. 1998. Tumor immunology: the glass is half full. Immunity 9:757–763PubMedCrossRefGoogle Scholar
  2. 2.
    Blattman, J.N., and P.D. Greenberg. 2004. Cancer Immunotherapy: A treatment for the masses. Science 305:200–205PubMedCrossRefGoogle Scholar
  3. 3.
    Bendelac, A., M.N. Rivera, S.H. Park, and J.H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15:535–562PubMedCrossRefGoogle Scholar
  4. 4.
    Godfrey, D.I., H.R. MacDonald, M. Kronenberg, M.J. Smyth, and L. Van Kaer. 2004. NKT cells: what’s in a name? Nat Rev Immunol 4:231–237PubMedCrossRefGoogle Scholar
  5. 5.
    Godfrey, D.I., and M. Kronenberg. 2004. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379–1388PubMedCrossRefGoogle Scholar
  6. 6.
    Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23:877–900PubMedCrossRefGoogle Scholar
  7. 7.
    Brigl, M., and M.B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu Rev Immunol 22:817–890PubMedCrossRefGoogle Scholar
  8. 8.
    Dellabona, P., E. Padovan, G. Casorati, M. Brockhaus, and A. Lanzavecchia. 1994. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4–8- T cells. J Exp Med 180:1171–1176PubMedCrossRefGoogle Scholar
  9. 9.
    Gadola, S.D., N. Dulphy, M. Salio, and V. Cerundolo. 2002. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol 168:5514–5520PubMedGoogle Scholar
  10. 10.
    Slifka, M.K., R.R. Pagarigan, and J.L. Whitton. 2000. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells [published erratum appears in J Immunol 2000 Mar 15;164(6):following 3444]. J Immunol 164:2009–2015PubMedGoogle Scholar
  11. 11.
    Gumperz, J.E., C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S.A. Porcelli, S. Cardell, M.B. Brenner, and S.M. Behar. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211–221PubMedCrossRefGoogle Scholar
  12. 12.
    Hayakawa, Y., D.I. Godfrey, and M.J. Smyth. 2004. Alpha-galactosylceramide: potential immunomodulatory activity and future application. Curr Med Chem 11:241–252PubMedCrossRefGoogle Scholar
  13. 13.
    Sidobre, S., O.V. Naidenko, B.C. Sim, N.R. Gascoigne, K.C. Garcia, and M. Kronenberg. 2002. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J Immunol 169:1340–1348PubMedGoogle Scholar
  14. 14.
    Wu, D.Y., N.H. Segal, S. Sidobre, M. Kronenberg, and P.B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198:173–181PubMedCrossRefGoogle Scholar
  15. 15.
    Schofield, L., M.J. McConville, D. Hansen, A.S. Campbell, B. Fraser-Reid, M.J. Grusby, and S.D. Tachado. 1999. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 283:225–229PubMedCrossRefGoogle Scholar
  16. 16.
    Rauch, J., J. Gumperz, C. Robinson, M. Skold, C. Roy, D.C. Young, M. Lafleur, D.B. Moody, M.B. Brenner, C.E. Costello, and S.M. Behar. 2003. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem 278:47508–47515PubMedCrossRefGoogle Scholar
  17. 17.
    Ortaldo, J.R., H.A. Young, R.T. Winkler-Pickett, E.W. Bere, Jr., W.J. Murphy, and R.H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 172:943–953PubMedGoogle Scholar
  18. 18.
    Zhou, D., J. Mattner, C. Cantu, 3rd, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y.P. Wu, T. Yamashita, S. Teneberg, D. Wang, R.L. Proia, S.B. Levery, P.B. Savage, L. Teyton, and A. Bendelac. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Sciencebreak 306:1786–1789Google Scholar
  19. 19.
    Mattner, J., K.L. Debord, N. Ismail, R.D. Goff, C. Cantu, 3rd, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, K. Hoebe, O. Schneewind, D. Walker, B. Beutler, L. Teyton, P.B. Savage, and A. Bendelac. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525–529PubMedCrossRefGoogle Scholar
  20. 20.
    Kinjo, Y., D. Wu, G. Kim, G.W. Xing, M.A. Poles, D.D. Ho, M. Tsuji, K. Kawahara, C.H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520–525PubMedCrossRefGoogle Scholar
  21. 21.
    Wu, D., G.W. Xing, M.A. Poles, A. Horowitz, Y. Kinjo, B. Sullivan, V. Bodmer-Narkevitch, O. Plettenburg, M. Kronenberg, M. Tsuji, D.D. Ho, and C.H. Wong. 2005. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A 102:1351–1356Google Scholar
  22. 22.
    Moody, D.B., D.C. Young, T.Y. Cheng, J.P. Rosat, C. Roura-Mir, P.B. O’Connor, D.M. Zajonc, A. Walz, M.J. Miller, S.B. Levery, I.A. Wilson, C.E. Costello, and M.B. Brenner. 2004. T cell activation by lipopeptide antigens. Science 303:527–531PubMedCrossRefGoogle Scholar
  23. 23.
    Matsuda, J.L., L. Gapin, J.L. Baron, S. Sidobre, D.B. Stetson, M. Mohrs, R.M. Locksley, and M. Kronenberg. 2003. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A 100:8395–8400Google Scholar
  24. 24.
    Stetson, D.B., M. Mohrs, R.L. Reinhardt, J.L. Baron, Z.E. Wang, L. Gapin, M. Kronenberg, and R.M. Locksley. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 198:1069–1076PubMedCrossRefGoogle Scholar
  25. 25.
    Carnaud, C., D. Lee, O. Donnars, S.H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:4647–4650PubMedGoogle Scholar
  26. 26.
    Eberl, G., and H.R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30:985–992PubMedCrossRefGoogle Scholar
  27. 27.
    Vincent, M.S., D.S. Leslie, J.E. Gumperz, X. Xiong, E.P. Grant, and M.B. Brenner. 2002. CD1-dependent dendritic cell instruction. Nat Immunol 3:1163–1168PubMedCrossRefGoogle Scholar
  28. 28.
    Smyth, M.J., N.Y. Crowe, D.G. Pellicci, K. Kyparissoudis, J.M. Kelly, K. Takeda, H. Yagita, and D.I. Godfrey. 2002. Sequential production of interferon-gamma by NK1. 1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99:h1259–1266. Google Scholar
  29. 29.
    Galli, G., S. Nuti, S. Tavarini, L. Galli-Stampino, C. De Lalla, G. Casorati, P. Dellabona, and S. Abrignani. 2003. CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes. J Exp Med 197:1051–1057PubMedCrossRefGoogle Scholar
  30. 30.
    Hermans, I.F., J.D. Silk, U. Gileadi, M. Salio, B. Mathew, G. Ritter, R. Schmidt, A.L. Harris, L. Old, and V. Cerundolo. 2003. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171:5140–5147PubMedGoogle Scholar
  31. 31.
    Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198:267–279PubMedCrossRefGoogle Scholar
  32. 32.
    Fujii, S., K. Liu, C. Smith, A.J. Bonito, and R.M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199:1607–1618PubMedCrossRefGoogle Scholar
  33. 33.
    Chen, Y.G., C.M. Choisy-Rossi, T.M. Holl, H.D. Chapman, G.S. Besra, S.A. Porcelli, D.J. Shaffer, D. Roopenian, S.B. Wilson, and D.V. Serreze. 2005. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 174:1196–1204PubMedGoogle Scholar
  34. 34.
    Gumperz, J.E., S. Miyake, T. Yamamura, and M.B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195:625–636PubMedCrossRefGoogle Scholar
  35. 35.
    Lee, P.T., K. Benlagha, L. Teyton, and A. Bendelac. 2002. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195:637–641PubMedCrossRefGoogle Scholar
  36. 36.
    Smyth, M.J., N.Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D.I. Godfrey. 2002. NKT cells - conductors of tumor immunity? Curr Opin Immunol 14:165–171PubMedCrossRefGoogle Scholar
  37. 37.
    Smyth, M.J., and D.I. Godfrey. 2000. NKT cells and tumor immunity–a double-edged sword. Nat Immunol 1:459–460PubMedCrossRefGoogle Scholar
  38. 38.
    Wilson, S.B., and T.L. Delovitch. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3:211–222PubMedCrossRefGoogle Scholar
  39. 39.
    Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Va 14 NKT cells by glycosylceramides. Science 278: 1623–1626.PubMedCrossRefGoogle Scholar
  40. 40.
    Kawano, T., T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, T. Fujisawa, H. Shinkai, and M. Taniguchi. 1999. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59:5102–5105PubMedGoogle Scholar
  41. 41.
    Hayakawa, Y., S. Rovero, G. Forni, and M.J. Smyth. 2003. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 100:9464–9469PubMedCrossRefGoogle Scholar
  42. 42.
    Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31:1720–1727PubMedCrossRefGoogle Scholar
  43. 43.
    Hayakawa, Y., K. Takeda, H. Yagita, M.J. Smyth, L. Van Kaer, K. Okumura, and I. Saiki. 2002. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100:1728–1733PubMedGoogle Scholar
  44. 44.
    Schmieg, J., G. Yang, R.W. Franck, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198:1631–1641PubMedCrossRefGoogle Scholar
  45. 45.
    Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, M. Taniguchi, and T. Nishimura. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189:1121–1128PubMedCrossRefGoogle Scholar
  46. 46.
    Smyth, M.J., N.Y. Crowe, and D.I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:459–463PubMedCrossRefGoogle Scholar
  47. 47.
    Crowe, N.Y., M.J. Smyth, and D.I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119–127PubMedCrossRefGoogle Scholar
  48. 48.
    Nishikawa, H., T. Kato, K. Tanida, A. Hiasa, I. Tawara, H. Ikeda, Y. Ikarashi, H. Wakasugi, M. Kronenberg, T. Nakayama, M. Taniguchi, K. Kuribayashi, L.J. Old, and H. Shiku. 2003. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 100:10902–10906PubMedCrossRefGoogle Scholar
  49. 49.
    Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515–520PubMedCrossRefGoogle Scholar
  50. 50.
    Ostrand-Rosenberg, S., V.K. Clements, M. Terabe, J.M. Park, J.A. Berzofsky, and S.K. Dissanayake. 2002. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 169:5796–5804PubMedGoogle Scholar
  51. 51.
    Terabe, M., S. Matsui, J.M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, J.J. Letterio, W.E. Paul, and J.A. Berzofsky. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741–1752PubMedCrossRefGoogle Scholar
  52. 52.
    Moodycliffe, A.M., D. Nghiem, G. Clydesdale, and S.E. Ullrich. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 1:521–525PubMedCrossRefGoogle Scholar
  53. 53.
    Sharif, S., G.A. Arreaza, P. Zucker, Q.S. Mi, J. Sondhi, O.V. Naidenko, M. Kronenberg, Y. Koezuka, T.L. Delovitch, J.M. Gombert, M. Leite-De-Moraes, C. Gouarin, R. Zhu, A. Hameg, T. Nakayama, M. Taniguchi, F. Lepault, A. Lehuen, J.F. Bach, and A. Herbelin. 2001. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7:1057–1062PubMedCrossRefGoogle Scholar
  54. 54.
    Smyth, M.J., N.Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D.I. Godfrey. 2002. NKT cells - conductors of tumor immunity? Curr Opin Immunol 14:165–171PubMedCrossRefGoogle Scholar
  55. 55.
    Tahir, S.M., O. Cheng, A. Shaulov, Y. Koezuka, G.J. Bubley, S.B. Wilson, S.P. Balk, and M.A. Exley. 2001. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167:4046–4050PubMedGoogle Scholar
  56. 56.
    Dhodapkar, M.V., M.D. Geller, D.H. Chang, K. Shimizu, S. Fujii, K.M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667–1676PubMedCrossRefGoogle Scholar
  57. 57.
    Dhodapkar, K.M., B. Cirignano, F. Chamian, D. Zagzag, D.C. Miller, J.L. Finlay, and R.M. Steinman. 2004. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109:h893–899. Google Scholar
  58. 58.
    Metelitsa, L.S., O.V. Naidenko, A. Kant, H.W. Wu, M.J. Loza, B. Perussia, M. Kronenberg, and R.C. Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167:3114–3122PubMedGoogle Scholar
  59. 59.
    Giaccone, G., C.J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B.M. von Blomberg, R.J. Scheper, H.J. van der Vliet, A.J. van den Eertwegh, M. Roelvink, J. Beijnen, H. Zwierzina, and H.M. Pinedo. 2002. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709PubMedGoogle Scholar
  60. 60.
    Fujii, S., K. Shimizu, R.M. Steinman, and M.V. Dhodapkar. 2003. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 272:147–159PubMedCrossRefGoogle Scholar
  61. 61.
    van der Vliet, H.J., J.W. Molling, N. Nishi, A.J. Masterson, W. Kolgen, S.A. Porcelli, A.J. van den Eertwegh, B.M. von Blomberg, H.M. Pinedo, G. Giaccone, and R.J. Scheper. 2003. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 63:h4101–4106. Google Scholar
  62. 62.
    Fujii, S., K. Shimizu, M. Kronenberg, and R.M. Steinman. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3:867–874PubMedCrossRefGoogle Scholar
  63. 63.
    Nieda, M., M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D.J. Macfarlane, and A.J. Nicol. 2004. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383–389PubMedCrossRefGoogle Scholar
  64. 64.
    Chang, D.H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, J. Shay, K. Kirchhoff, N. Nishi, Y. Ando, K. Hayashi, H. Hassoun, R.M. Steinman, and M.V. Dhodapkar. 2005. Sustained expansion of NKT cells and antigen-specific hT cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503–1517PubMedCrossRefGoogle Scholar
  65. 65.
    Fujii, S.I., K. Shimuzu, M. Kronenberg, and R.M. Steinman. 2002. Prolonged interferon-g producing NKT responses induced with a-galactosyl ceramide loaded dendritic cells. Nature Immunol 3:867–874.CrossRefGoogle Scholar
  66. 66.
    Steinman, R.M., and M. Dhodapkar. 2001. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Madhav V. Dhodapkar
    • 1
  1. 1.Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY; and Hematology ServiceMemorial Sloan Kettering Cancer CenterNew York

Personalised recommendations